Table 1.

Demographics and co-morbidities in patients with and without IBD.

	IBD N=49	No IBD N=96	P
Median Age (Years) at CGD Diagnosis (Range)	1.5# (<1–16)	1# (<1–18)	0.452
Median Age (Years) at Allogeneic HCT (Range)	11 (1–26)	5 (<1–21)	<0.001
Genetic Mutation (Protein Deficiency)
CYBA (p22phox)	2 (4.1%)	6 (6.3%)	0.172
NCF4 (p40phox)	1 (2.0%)
NCF1 (p47phox)	2 (4.1%)	15 (15.6%)
NCF2 (p67phox)	1 (2.0%)	3 (3.1%)
CYBB (gp91phox)	40 (81.6%)	66 (68.8%)
Unknown	3 (6.1%)	6 (6.2%)
Oxidase Function
Unable to Be Determined	6 (12.2%)	16 (16.7%)	0.718
Oxidase Null	28 (57.1%)	55 (57.3%)
Oxidase Positive	15 (30.6%)	25 (26.0%)
History of Infection(s) Within 1 Year Prior to Allogeneic HCT	38 (77.6%)	64 (66.7%)	0.175
Staphylococcus Aureus	1 (2.0%)	8 (8.3%)	0.137
Nocardia Species Infection	1 (2.0%)	4 (4.2%)	0.507
Aspergillus Species Infection	7 (14.3%)	17 (17.7%)	0.600
History of Pneumonia Within 1 Year Prior to Allogeneic HCT	23 (46.9%)	37 (38.5%)	0.332
History of Lung Resection	3 (6.1%)	8 (8.4%)	0.623
History of Liver Resection	1 (2.0%)	0 (0%)	0.162
History of Gastrointestinal Resection	0	0	N/A
Median Albumin g/dL (Range)	3.5@ (1.7–4.4)	3.8@ (2.5–5.0)	<0.001
Weight <5th Percentile for Age	17* (35.4%)	14 (14.6%)	0.004
Height <5th Percentile for Age	24∧ (51.1%)	25 (26.0%)	0.003
Lansky or Karnofsky Score <90 Prior to Allogeneic HCT	10+ (20.4%)	5+ (5.2%)	0.007
Received IBD Therapy	47− (97.9%)
IBD Controlled Prior to Allogeneic HCT	32$ (65%)

^#Age at diagnosis was reported for 24 IBD patients and 71 patients without IBD

^@Albumin data was reported for 48 IBD patients and 92 patients without IBD

^*Weight data was reported for 48 IBD patients

^∧Height data was reported for 47 IBD patients

⁺Lansky or Karnofsky was unknown for 1 IBD patient and 9 patients without IBD

⁻IBD therapy was reported for 48 IBD patients

^$IBD status was reported for 48 IBD patients (and reported as unknown for 1 IBD Patient)